Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Validation of suPAR turbidimetric assay on Cobas® (c502 and c702) and comparison to suPAR ELISA

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Soluble Urokinase Receptor (SuPAR) in COVID-19-Related AKI

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Association Between Elevated suPAR, a New Biomarker of Inflammation, and Accelerated Aging

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Elevated suPAR Is an Independent Risk Marker for Incident Kidney Disease in Acute Medical Patients

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

suPAR is a plasma marker of chronic inflammation, and an elevated suPAR is consistently associated with worse outcome in a variety of clinical conditions. Quantification of suPAR is useful for determining patient risk in triage, but there is no fast automatized method for quick determination of suPAR. We developed and validated a rapid latex particle-enhanced turbidimetric immunoassay for quantification of plasma suPAR on the c502 and the c702 Roche Cobas® 8000 measurment systems. The turbidimetric assay was validated against the suPARnostic® ELISA (ViroGates, Denmark). This validation demonstrates suPAR can be analysed by turbidimetry giving very similar results (<15% difference) compared to the ELISA method and the observed correlations (n = 103) were strong, r > 0.95. Roche Cobas® 8000 instruments demonstrated repeatability and repoducibility, CV % at 3.4-4.1 and 5.7-11.4, respectively. The estimated limit of detection was 1.30 µg/L and 1.31 µg/L for the Cobas® c502 and c702, respectively. Dilution tests showed linearity of suPAR from 1.8 to 26.5 μg/L. The acceptable concentrations of Bilirubin, Intralipid and Hemoglobin, were 350 µmol/L, 3.3 g/L and 1.4 g/L, respectively. suPAR can be quantified reproducibly within 10 min using a turbidimetry assay. This assay is faster than ELISA with similar results, making it suitable for clinical routine analysis.

Original languageEnglish
JournalScandinavian Journal of Clinical and Laboratory Investigation
Issue number4
Pages (from-to)327-335
Number of pages9
Publication statusPublished - Jul 2020

    Research areas

  • biomarker, ELISA, immunoturbidimetry assay, Receptors, soluble urokinase plasminogen activator, validation studies

ID: 59613983